NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

BRIEF-Zymeworks Says ZW25 Was Shown To Be Well Tolerated Across A Range Of Tumor Types in Phase 1 Study

Published 2018-06-01, 03:55 p/m
BRIEF-Zymeworks Says ZW25 Was Shown To Be Well Tolerated Across A Range Of Tumor Types in Phase 1 Study
ZYME
-

June 1 (Reuters) - Zymeworks Inc ZYME.TO :

* CLINICAL DATA FOR ZYMEWORKS' NOVEL BISPECIFIC ANTIBODY, ZW25, PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

* ZW25 SHOWN TO BE ACTIVE AND WELL TOLERATED ACROSS A RANGE OF TUMOR TYPES

* POTENTIAL PHASE 2/3 STUDY FOR ZW25 COULD BEGIN AS EARLY AS H2 2019 PENDING DISCUSSION WITH U.S. FDA

* TREATMENT-RELATED ADVERSE EVENTS PRIMARILY GRADE 1/2, NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS/DISCONTINUATIONS SEEN FOR ZW25 IN STUDY

* STUDIES TO EVALUATE COMBINATIONS WITH ZW25 BEYOND THOSE ONGOING IN CURRENT PHASE 1 STUDY PLANNED TO START LATER THIS YEAR

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.